Solara Active Pharma Sciences Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹354.35
- Today's High:
- ₹366.75
- Open Price:
- ₹365
- 52W Low:
- ₹326
- 52W High:
- ₹494.9
- Prev. Close:
- ₹361.7
- Volume:
- 17407
Company Statistics
- Market Cap.:
- ₹13.18 billion
- Book Value:
- 417.833
- Revenue TTM:
- ₹14.66 billion
- Operating Margin TTM:
- 2.15%
- Gross Profit TTM:
- ₹6.05 billion
- Profit Margin:
- -1.73%
- Return on Assets TTM:
- 0.49%
- Return on Equity TTM:
- -1.47%
Company Profile
Solara Active Pharma Sciences Limited had its IPO on under the ticker symbol SOLARA.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Solara Active Pharma Sciences Limited has a staff strength of 2,361 employees.
Stock update
Shares of Solara Active Pharma Sciences Limited opened at ₹365 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹354.35 - ₹366.75, and closed at ₹356.5.
This is a -1.44% slip from the previous day's closing price.
A total volume of 17,407 shares were traded at the close of the day’s session.
In the last one week, shares of Solara Active Pharma Sciences Limited have slipped by -0.94%.
Solara Active Pharma Sciences Limited's Key Ratios
Solara Active Pharma Sciences Limited has a market cap of ₹13.18 billion, indicating a price to book ratio of 0 and a price to sales ratio of 0.
In the last 12-months Solara Active Pharma Sciences Limited’s revenue was ₹14.66 billion with a gross profit of ₹6.05 billion and an EBITDA of ₹1.44 billion. The EBITDA ratio measures Solara Active Pharma Sciences Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Solara Active Pharma Sciences Limited’s operating margin was 2.15% while its return on assets stood at 0.49% with a return of equity of -1.47%.
In Q2, Solara Active Pharma Sciences Limited’s quarterly earnings growth was a positive 98.4% while revenue growth was a positive 6.7%.
Solara Active Pharma Sciences Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at ₹-6.97 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Solara Active Pharma Sciences Limited’s profitability.
Solara Active Pharma Sciences Limited stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.
Solara Active Pharma Sciences Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹28.99 billion
- Total Liabilities
- ₹11.01 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 0%
Solara Active Pharma Sciences Limited ended 2024 with ₹28.99 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹28.99 billion while shareholder equity stood at ₹15.00 billion.
Solara Active Pharma Sciences Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹11.01 billion in other current liabilities, in common stock, ₹0 in retained earnings and ₹3.65 billion in goodwill. Its cash balance stood at ₹87.30 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹2.35 billion.
Solara Active Pharma Sciences Limited’s total current assets stands at ₹11.87 billion while long-term investments were ₹0 and short-term investments were ₹133.90 million. Its net receivables were ₹5.37 billion compared to accounts payable of ₹3.06 billion and inventory worth ₹5.58 billion.
In 2024, Solara Active Pharma Sciences Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Solara Active Pharma Sciences Limited paid ₹0 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹356.5
- 52-Week High
- ₹494.9
- 52-Week Low
- ₹326
- Analyst Target Price
- ₹
Solara Active Pharma Sciences Limited stock is currently trading at ₹356.5 per share. It touched a 52-week high of ₹494.9 and a 52-week low of ₹494.9. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹378.93 and 200-day moving average was ₹387.15 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 6075.2% of the company’s stock are held by insiders while 1885% are held by institutions.
Frequently Asked Questions About Solara Active Pharma Sciences Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India. The company offers APIs for anesthetics, anthelmintic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-viral, antibiotic, anticoagulant, anticonvulsant, antidepressant, antiemetic, antifungal, antigout agent, antihistamine, antihyperlipoproteinemic, antimycotic, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antiulcerative, anxiolytic, bile acid analogue, calcimimetic agent, cardiovascular agent, chronic alcoholism, chronic kidney disease, dopamine receptor antagonist, folate analog, hyperkalaemia, immunosuppressant, loop diuretic, OAB treatment, phenylalanine reducer, phosphate binder, reversal of neuro-muscular blocking agent, skeletal muscle relaxant, topical anti-infectives, treatment of hyperphosphatemia, hemorrheologic agent, hypercholesterolemia, hypophosphatemic agent, nucleoside inhibitor, aprepitant, NSAIDs, and type-II diabetes therapeutic categories. It also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical services, impurity synthesis, and regulatory support. In addition, the company also exports its products. It operates in the Asia Pacific, Europe, North America, South America, and internationally. The company was formerly known as SSL Pharma Sciences Limited and changed its name to Solara Active Pharma Sciences Limited in March 2017. Solara Active Pharma Sciences Limited was incorporated in 2017 and is based in Chennai, India.